Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.

× No keyword cloud information.

19 in total

1. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.

Authors: Jennifer L Clarke; William Pao; Nian Wu; Vincent A Miller; Andrew B Lassman
Journal: J Neurooncol Date: 2010-02-10 Impact factor: 4.130

Review 2. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies.

Authors: Chiara D'Antonio; Antonio Passaro; Bruno Gori; Ester Del Signore; Maria Rita Migliorino; Serena Ricciardi; Alberto Fulvi; Filippo de Marinis
Journal: Ther Adv Med Oncol Date: 2014-05 Impact factor: 8.168

Review 3. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.

Authors: Matthias Scheffler; Paola Di Gion; Oxana Doroshyenko; Jürgen Wolf; Uwe Fuhr
Journal: Clin Pharmacokinet Date: 2011-06 Impact factor: 6.447

Review 4. Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches.

Authors: Giuseppe Lombardi; Fable Zustovich; Patrizia Farina; Alessandro Della Puppa; Renzo Manara; Diego Cecchin; Antonella Brunello; Alessandro Cappetta; Vittorina Zagonel
Journal: Oncologist Date: 2011-07-27

5. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations.

Authors: Kartik Sehgal; Deepa Rangachari; Paul A VanderLaan; Susumu S Kobayashi; Daniel B Costa
Journal: Oncologist Date: 2020-10-06

6. EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy.

Authors: Seerat Poonia; Eamon M Berge; Dara L Aisner; Denise Damek; Robert C Doebele
Journal: Clin Lung Cancer Date: 2014-05-15 Impact factor: 4.785

7. Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases.

Authors: Rimas V Lukas; Martin Kelly Nicholas; Victoria Villaflor; Philip C Hoffman; Ravi Salgia
Journal: J Neurol Res Date: 2012-02-01

8. Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101).

Authors: Kaname Nosaki; Takeharu Yamanaka; Akinobu Hamada; Yoshimasa Shiraishi; Taishi Harada; Daisuke Himeji; Takeshi Kitazaki; Noriyuki Ebi; Takayuki Shimose; Takashi Seto; Mitsuhiro Takenoyama; Kenji Sugio
Journal: Oncologist Date: 2020-08-11

Review 9. EGFR mutation status in brain metastases of non-small cell lung carcinoma.

Authors: Fanny Burel-Vandenbos; Damien Ambrosetti; Michael Coutts; Florence Pedeutour
Journal: J Neurooncol Date: 2012-10-20 Impact factor: 4.130

10. Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation.

Authors: Katsuhiro Masago; Yosuke Togashi; Masahide Fukudo; Tomohiro Terada; Kaoru Irisa; Yuichi Sakamori; Shiro Fujita; Young Hak Kim; Tadashi Mio; Ken-Ichi Inui; Michiaki Mishima
Journal: Case Rep Oncol Date: 2010-04-22